Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active Psoriatic Arthritis: Results from a Phase 2 Trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 2, p. s383, 2024. DOI: 10.25251/skin.8.supp.383. Disponível em: https://skin.dermsquared.com/skin/article/view/2678. Acesso em: 19 apr. 2025.